Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...